<DOC>
	<DOCNO>NCT00612534</DOCNO>
	<brief_summary>The purpose study evaluate three different dosage strength sublingual ARX-F01 ( Sufentanil NanoTab ) versus sublingual Placebo NanoTab treatment post-operative pain subject follow total knee replacement surgery . We hypothesize subject receive placebo poor pain relief drop study sooner often ARX-F01-treated subject .</brief_summary>
	<brief_title>A Multicenter , Randomized , Placebo-Controlled Phase 2 Study Evaluate Clinical Efficacy , Safety , Tolerability ARX-F01 Sublingual Sufentanil Patients Undergoing Elective Unilateral Total Knee Replacement</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Sufentanil</mesh_term>
	<criteria>Male female patient 45 80 year age . Patient schedule elective , unilateral , unicondylar , bi tricompartmental , cement uncemented knee replacement general spinal anesthesia include use intrathecal opioid . Patient must classify American Society Anesthesiologists ( ASA ) class I III . Patient must Body Mass Index [ BMI = weight ( kg ) /height ( m2 ) ] 18 39 , inclusively . Female patient childbearing potential must use effective method birth control screen visit end study . Acceptable method birth control include oral transdermal contraceptive , condom , spermicidal foam , intrauterine device ( IUD ) , progestin implant injection , abstinence , vaginal ring , sterilization partner . The reason nonchildbearing potential , bilateral tubal ligation , bilateral oophorectomy , hysterectomy , postmenopausal ≥1 year , must specify patient 's case report form ( CRF ) . The patient must willing able understand study procedure use pain scale , communicate meaningfully study personnel . The patient must provide write informed consent sign Informed Consent approve Institutional Review Board ( IRB ) . Patient previously undergone knee replacement knee . A passive rangeofmotion ( PRM ) use 12hour study period complete Patient previously respond opioid analgesic treatment pain . Patient currently take take opioid 30 consecutive day daily use daily dose equivalent great 15 mg morphine within past 3 month prior surgery ( e.g . 3 dos per day Vicodin® , Norco® , Lortab® 5 mg hydrocodone per tablet ) . Patient allergy hypersensitivity opioids . Patient currently sleep apnea document sleep laboratory study . Patient screen laboratory test value outside laboratory normal range consider clinically significant Investigator . Patient contraindication use general anesthesia . Patient woman pregnant lactating . Patient psychiatric disease encephalopathy severe enough prevent patient provide reliable study documentation . Patient , Investigator 's judgment , adequate ability read understand English . Patient medical condition , Investigator 's opinion , could adversely impact patient 's participation safety , conduct study , interfere pain assessment , include fracture active infection . Patient clinically significant renal liver impairment could affect metabolism clearance sufentanil . Patient painful physical condition knee arthritis , opinion Investigator , may confound postoperative pain assessment . Patient history drug , prescription medicine , alcohol abuse within past 2 year positive test drug abuse screen . Patient receive oxygen therapy time screen . Patient participate clinical trial investigational drug device within 30 day screen visit schedule receive investigational product ARXF01 participate study . Exclusion Criteria Randomization ( early PACU time period ) : Patient respiratory rate le 8 breath per minute great 24 breath per minute , Patient arterial oxygen saturation pulse oximetry ( SpO2 ) less 90 % supplemental oxygen . Patient able answer question follow command . Patient vomit responsive standard treatment . The surgical procedure incision closure longer 3 hour . There deviation surgical anesthetic protocol specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>